New York State Teachers Retirement System Has $56.63 Million Position in Becton, Dickinson and Company (NYSE:BDX)

New York State Teachers Retirement System reduced its position in shares of Becton, Dickinson and Company (NYSE:BDX) by 5.0% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 234,888 shares of the medical instruments supplier’s stock after selling 12,490 shares during the period. New York State Teachers Retirement System’s holdings in Becton, Dickinson and Company were worth $56,631,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently modified their holdings of BDX. Nordea Investment Management AB boosted its position in shares of Becton, Dickinson and Company by 277.3% during the first quarter. Nordea Investment Management AB now owns 1,936,654 shares of the medical instruments supplier’s stock worth $478,295,000 after buying an additional 1,423,353 shares during the period. PineStone Asset Management Inc. boosted its position in shares of Becton, Dickinson and Company by 141.6% during the second quarter. PineStone Asset Management Inc. now owns 1,345,873 shares of the medical instruments supplier’s stock worth $314,544,000 after buying an additional 788,735 shares during the period. M&G Plc acquired a new position in shares of Becton, Dickinson and Company during the first quarter worth about $173,692,000. First Eagle Investment Management LLC boosted its position in shares of Becton, Dickinson and Company by 32.5% during the second quarter. First Eagle Investment Management LLC now owns 2,803,255 shares of the medical instruments supplier’s stock worth $655,149,000 after buying an additional 688,296 shares during the period. Finally, Bank of New York Mellon Corp boosted its position in shares of Becton, Dickinson and Company by 8.5% during the second quarter. Bank of New York Mellon Corp now owns 4,412,163 shares of the medical instruments supplier’s stock worth $1,031,167,000 after buying an additional 346,720 shares during the period. 86.97% of the stock is owned by institutional investors and hedge funds.

Becton, Dickinson and Company Price Performance

NYSE:BDX opened at $236.61 on Thursday. The company has a quick ratio of 1.36, a current ratio of 1.85 and a debt-to-equity ratio of 0.70. The stock’s 50 day moving average price is $237.62 and its two-hundred day moving average price is $235.05. The firm has a market capitalization of $68.38 billion, a price-to-earnings ratio of 52.12, a P/E/G ratio of 1.79 and a beta of 0.42. Becton, Dickinson and Company has a 12-month low of $218.75 and a 12-month high of $259.92.

Becton, Dickinson and Company (NYSE:BDX) last released its quarterly earnings data on Thursday, August 1st. The medical instruments supplier reported $3.50 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.31 by $0.19. Becton, Dickinson and Company had a return on equity of 14.49% and a net margin of 7.13%. The firm had revenue of $4.99 billion for the quarter, compared to analyst estimates of $5.08 billion. During the same quarter in the prior year, the company earned $2.96 earnings per share. The business’s revenue for the quarter was up 2.3% compared to the same quarter last year. On average, analysts anticipate that Becton, Dickinson and Company will post 13.11 earnings per share for the current year.

Analyst Ratings Changes

Several analysts recently issued reports on the company. StockNews.com upgraded Becton, Dickinson and Company from a “hold” rating to a “buy” rating in a report on Thursday, August 8th. Citigroup upgraded Becton, Dickinson and Company from a “neutral” rating to a “buy” rating and upped their target price for the stock from $255.00 to $275.00 in a report on Tuesday, October 1st. Raymond James dropped their target price on Becton, Dickinson and Company from $275.00 to $270.00 and set an “outperform” rating on the stock in a report on Friday, August 2nd. Evercore ISI upped their target price on Becton, Dickinson and Company from $286.00 to $290.00 and gave the stock an “outperform” rating in a report on Tuesday, October 1st. Finally, Stifel Nicolaus upped their target price on Becton, Dickinson and Company from $270.00 to $280.00 and gave the stock a “buy” rating in a report on Friday, July 26th. Nine investment analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company has a consensus rating of “Buy” and an average price target of $282.63.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.